Currently more than 20 inhalers are approved for the management of COPD and marketed in North America. About half are single medication inhalers and half are combination medication inhalers. This ...

Triple therapy of an inhaled corticosteroid, long acting β 2-agonist (LABA), and long acting muscarinic antagonist (LAMA) is more effective in reducing the annual rate of exacerbations compared with ...

Do inhaled corticosteroids elevate ... trials in which more than 7000 patients with COPD were randomized to inhaled budesonide or placebo, with or without the long-acting β 2-agonist formoterol ...

Objectives Inhaled corticosteroids (ICS) reduce exacerbation rates and the decline in lung function in people with chronic obstructive pulmonary disease (COPD). There is evidence that smoking causes ...

Background: There is controversy about whether therapy with inhaled corticosteroids (ICSs) modifies the natural history of COPD, characterized by an accelerated decline in FEV 1. Methods ...

Background Whether inhaled corticosteroids (ICSs) reduce major adverse cardiovascular events (MACEs) in people with chronic obstructive pulmonary disease (COPD) is debated ... to enable patient ...

uea.ac.uk Background The effect of inhaled corticosteroids (ICS) on fracture risk in patients with chronic obstructive pulmonary disease (COPD) remains uncertain. The aim of this study was to evaluate ...

A recent study published in the Journal of the COPD Foundation examines errors in the use or design of inhalers used by ...

Objectives Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect of inhaled COPD treatments on CVD outcomes and safety in patients with ...